Immunology and vaccines and nanovaccines for Helicobacter pylori infection

Reference

• Rothenbacher D, Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003;5(8):693-703
   PubMed Web of Science ®Google Scholar
• Frenck RWJr, Clemens J. Helicobacter in the developing world. Microbes Infect 2003;5(8):705-13
   PubMedGoogle Scholar
• Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-90
   PubMed Web of Science ®Google Scholar
• Konturek P, Konturek S, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol 2009;60(3):3-21
   PubMed Web of Science ®Google Scholar
• Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011;29(5):459-64
   PubMedGoogle Scholar
• O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter 2011;16(s1):53-8
   PubMedGoogle Scholar
• Milani M, Ghotaslou R, Akhi MT, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother 2012;18(6):848-52
   PubMedGoogle Scholar
• Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev vaccines 2009;8(8):1037-49
   PubMed Web of Science ®Google Scholar
• Tang R-X, Luo D-J, Sun A-H, Yan J. Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies. World J Gastroenterol 2008;14(30):4816
   PubMedGoogle Scholar
• Agarwal K, Agarwal S. editors. Helicobacter pylori Vaccine: from Past to Future. Mayo Clin Proc 2008;83(2):169-75
   PubMedGoogle Scholar
• Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 2012;18(12):1279
   PubMedGoogle Scholar
• Moise L, Moss SF, De Groot AS. Moving Helicobacter pylori vaccine development forward with bioinformatics and immunomics. Exp Rev Vaccines 2012;11(9):1031-3
   PubMed Web of Science ®Google Scholar
• Algood HMS, Cover TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev 2006;19(4):597-613
   PubMedGoogle Scholar
• Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights Into the Failure of the Immune Response and Perspectives on Vaccine Studies. Gastroenterology 2007;133(1):288-308
   PubMed Web of Science ®Google Scholar
• Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2008;1(2):123-35
   PubMedGoogle Scholar
• Robinson K, Argent RH, Atherton JC. The inflammatory and immune response to Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21(2):237-59
   PubMed Web of Science ®Google Scholar
• Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113(3):321-33
   PubMed Web of Science ®Google Scholar
• Smith MF, Mitchell A, Li G, et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. J Biol Chem 2003;278(35):32552-60
   PubMed Web of Science ®Google Scholar
• Boughan PK, Argent RH, Body-Malapel M, et al. Nucleotide-binding Oligomerization Domain-1 and Epidermal Growth Factor Receptor Critical Regulators Of β-Defensins During Helicobacter Pylori Infection. J Biol Chem 2006;281(17):11637-48
   PubMedGoogle Scholar
• Keep S, Borlace G, Butler R, Brooks D. Role of immune serum in the killing of Helicobacter pylori by macrophages. Helicobacter 2010;15(3):177-83
   PubMedGoogle Scholar
• Chmiela M, Michetti P. Inflammation, immunity, vaccines for Helicobacter infection. Helicobacter 2006;11(s1):21-6
   PubMedGoogle Scholar
• Oberhuber G, Bodingbauer M, Mosberger I, et al. High proportion of granzyme B-positive (activated) intraepithelial and lamina propria lymphocytes in lymphocytic gastritis. Am J Surg pathol 1998;22(4):450-8
   PubMedGoogle Scholar
• Amedei A, Della Bella C, Silvestri E, et al. T cells in gastric cancer: friends or foes. Clin Dev Immunol 2012;2012:690571
   PubMedGoogle Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182(1):18-32
   PubMed Web of Science ®Google Scholar
• Lee H, Chae S, Lee Y, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008;99(10):1704-11
   PubMed Web of Science ®Google Scholar
• Lundgren A, Trollmo C, Edebo A, et al. Helicobacter pylori-specific CD4+ T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun 2005;73(9):5612-19
   PubMedGoogle Scholar
• Wu C, Chen X, Liu J, et al. Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis. Helicobacter 2011;16(2):131-8
   PubMedGoogle Scholar
• Mueller A, Solnick JV. Inflammation, immunity, and vaccine development for Helicobacter pylori. Helicobacter. 2011;16(s1):26-32
   Google Scholar
• Mandell L, Moran AP, Cocchiarella A, et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004;72(11):6446-54
   PubMedGoogle Scholar
• Kido M, Watanabe N, Aoki N, et al. Dual roles of CagA protein in Helicobacter pylori-induced chronic gastritis in mice. Biochem Biophys Res Commun 2011;412(2):266-72
   PubMedGoogle Scholar
• El-Omar EM, Carrington M, et al. correction: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature 2001;412(6842):99
   PubMed Web of Science ®Google Scholar
• Santos J, Ladeira M, Pedrazzoli JJr, Ribeiro M. Relationship of IL-1 and TNF-α polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. Braz J Med Biol Res 2012;45(9):811-17
   PubMed Web of Science ®Google Scholar
• Tahara T, Shibata T, Yamashita H, et al. Synergistic effect of IL-1β and TNF-α polymorphisms on the H. pylori-related gastric pre-malignant condition. Hepatogastroenterology 2011;59(120):2416-20
   Google Scholar
• Partida-Rodríguez O, Torres J, Flores-Luna L, et al. Polymorphisms in TNF and HSP-70 show a significant association with gastric cancer and duodenal ulcer. Int J Cancer 2010;126(8):1861-8
   PubMedGoogle Scholar
• Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007;132(3):905-12
   PubMed Web of Science ®Google Scholar
• Lembo A, Caradonna L, Magrone T, et al. Helicobacter pylori infection, immune response and vaccination. Curr Drug Targets-Immune Endocr Metabol Disord 2001;1(3):199-208
   PubMedGoogle Scholar
• Akhiani AA, Schön K, Franzén LE, et al. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immun 2004;172(8):5024-33
   PubMedGoogle Scholar
• Bhuiyan TR, Saha A, Lundgren A, et al. Immune responses to Helicobacter pylori infection in Bangladeshi children during their first two years of life and the association between maternal antibodies and onset of infection. J Infect Dis 2010;202(11):1676-84
   PubMedGoogle Scholar
• Tummala S, Keates S, Kelly CP. Update on the immunologic basis of Helicobacter pylori gastritis. Current Opin Gastroenterol 2004;20(6):592-7
   PubMedGoogle Scholar
• Rothenbacher D, Bode G, Brenner H. History of breastfeeding and Helicobacter pylori infection in pre-school children: results of a population-based study from Germany. Int J Epidemiol 2002;31(3):632-7
   PubMed Web of Science ®Google Scholar
• Ueda M, Kikuchi S, Kasugai T, et al. Helicobacter pylori risk associated with childhood home environment. Cancer sci 2003;94(10):914-18
   PubMedGoogle Scholar
• Dore MP, Malaty HM, Graham DY, et al. Risk factors associated with Helicobacter pylori infection among children in a defined geographic area. Clin Infect Dis 2002;35(3):240-5
   PubMedGoogle Scholar
• Magalhães Queiroz DM, Luzza F. Epidemiology of Helicobacter pylori infection. Helicobacter 2006;11(s1):1-5
   PubMedGoogle Scholar
• Chong SK, Lou Q, Zollinger TW, et al. The seroprevalence of Helicobacter pylori in a referral population of children in the United States. Am J Gastroenterol 2003;98(10):2162-8
   PubMedGoogle Scholar
• Cravioto A, Tello A, Villafan H, et al. Inhibition of localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. J Infect Dis 1991;163(6):1247-55
   PubMed Web of Science ®Google Scholar
• Bessler HC, Oliveira IR, Giugliano LG. Human milk glycoproteins inhibit the adherence of Salmonella typhimurium to HeLa cells. Microbiol Immun 2006;50(11):877-82
   PubMedGoogle Scholar
• Futagami S, Takahashi H, Norose Y, Kobayashi M. Systemic and local immune responses against Helicobacter pylori urease in patients with chronic gastritis: distinct IgA and IgG productive sites. Gut 1998;43(2):168-75
   PubMedGoogle Scholar
• Clyne M, Thomas J, Weaver L, Drumm B. In vitro evaluation of the role of antibodies against Helicobacter pylori in inhibiting adherence of the organism to gastric cells. Gut 1997;40(6):731-8
   PubMedGoogle Scholar
• Grebowska A, Moran AP, Matusiak A, et al. Anti-phagocytic activity of Helicobacter pylori lipopolysaccharide (LPS)--possible modulation of the innate immune response to these bacteria. Pol J Microbiol 2008;57(3):185-92
   PubMedGoogle Scholar
• Tosi MF, Czinn SJ. Opsonic activity of specific human IgG against Helicobacter pylori. J Infect Dis 1990;162(1):156-62
   PubMedGoogle Scholar
• Allen LAH. Phagocytosis and persistence of Helicobacter pylori. Cell Microbiol 2007;9(4):817-28
   PubMedGoogle Scholar
• Desar I, Van Deuren M, Sprong T, et al. Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia. Clin Exp Immun 2009;156(3):434-9
   PubMed Web of Science ®Google Scholar
• Tanriverdi HA, Acun C, Ustundag G, et al. Investigation of human colostrum Helicobacter pylori IgA content in lactating women. Eur J Obstet Gynecol Reprod Biol 2006;124(1):58-60
   PubMedGoogle Scholar
• Korhonen H, Syväoja EL, Ahola-Luttila H, et al. Bactericidal effect of bovine normal and immune serum, colostrum and milk against Helicobacter pylori. J Appl Bacteriol 1995;78(6):655-62
   PubMedGoogle Scholar
• Korhonen H, Marnila P, Gill H. Bovine milk antibodies for health. Br J Nutr 2000;84(S1):135-46
   PubMedGoogle Scholar
• Ruggiero P. Helicobacter pylori and inflammation. Curr Pharm Des 2010;16(38):4225-36
   PubMedGoogle Scholar
• Bansil R, Celli JP, Hardcastle JM, Turner BS. The influence of mucus microstructure and rheology in Helicobacter pylori infection. Front Immunol 2013;4:310
   PubMedGoogle Scholar
• Kronsteiner B, Bassaganya-Riera J, Philipson N, Hontecillas R. Novel insights on the role of CD8+ T cells and cytotoxic responses during Helicobacter pylori infection. Gut microbes 2014;5(3):0-1
   Google Scholar
• Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter 2013;18(s1):18-23
   PubMedGoogle Scholar
• Otani K, Tanigawa T, Watanabe T, et al. Toll-like receptor 9 signaling has anti-inflammatory effects on the early phase of Helicobacter pylori-induced gastritis. Biochem Biophys Res commun 2012;426(3):342-9
   PubMedGoogle Scholar
• Horvath DJJr, Radin JN, Cho SH, et al. The interleukin-17 receptor B subunit is essential for the Th2 response to Helicobacter pylori, but not for control of bacterial burden. PLoS One 2013;8(3):e60363
   PubMedGoogle Scholar
• Kayhan B, Arasli M, Eren H, et al. Analysis of peripheral blood lymphocyte phenotypes and Th1/Th2 cytokines profile in the systemic immune responses of Helicobacter pylori infected individuals. Microbiol Immunol 2008;52(11):531-8
   PubMedGoogle Scholar
• Akbarzadeh A, Mikaeili H, Zarghami N, et al. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J nanomedicine 2012;7:511
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Zarghami N, Mikaeili H, et al. Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl 2012;5:13-25
   PubMedGoogle Scholar
• Davaran S, Akbarzadeh A, Nejati-Koshki K, et al. In Vitro Studies of NIPAAM-MAA-VP Copolymer-Coated Magnetic Nanoparticles for Controlled Anticancer Drug Release*. J Encapsulat Adsorpt Sci 2013;2013
   Google Scholar
• Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, et al. Molecular Target Therapy of AKT and NF-kB Signaling Pathways and Multidrug Resistance by Specific Cell Penetrating Inhibitor Peptides in HL-60 Cells. Asian Pac J Cancer Prev 2014;15(10):4353
   PubMedGoogle Scholar
• Valizadeh H, Mohammadi G, Ehyaei R, et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie-An Int J Pharm Sci 2012;67(1):63-8
   Google Scholar
• Nandedkar TD. Nanovaccines: recent developments in vaccination. J Bioscien 2009;34(6):995-1003
   PubMed Web of Science ®Google Scholar
• Rupnow MF, Chang AH, Shachter RD, et al. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009;200(8):1311-17
   PubMedGoogle Scholar
• Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer 2002;5(1):6-15
   PubMedGoogle Scholar
• Kikuchi S. Epidemiology of H. pylori infection and gastric mucosal atrophy. Nihon rinsho 2013;71(8):1331
   PubMedGoogle Scholar
• Yang X, Liu W, Yang W, et al. Oral immunization of mice with vaccine of attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Biomed Environ Sci 2005;18(6):411
   PubMedGoogle Scholar
• Guy B, Hessler C, Fourage S, et al. Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998;16(8):850-6
   PubMedGoogle Scholar
• Mori J, Vranac T, Smrekar B, et al. Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori. Vaccine 2012;30(40):5856-63
   PubMedGoogle Scholar
• Chen J, Lin L, Li N, She F. Enhancement of Helicobacter pylori outer inflammatory protein DNA vaccine efficacy by co-delivery of interleukin-2 and B subunit heat-labile toxin gene encoded plasmids. Microbiol Immun 2012;56(2):85-92
   PubMed Web of Science ®Google Scholar
• Presecki V, Katicić M, Kalenić S, et al. [A vaccine against Helicobacter pylori infection]. Lijec Vjesn 2002;124:79-82
   PubMedGoogle Scholar
• Zhang H, Zhang X, Liu M, et al. Expression and characterization of Helicobacter pylori heat-shock protein A (HspA) protein in transgenic tobacco (Nicotiana tabacum) plants. Biotechnol Appl Biochem 2006;43(1):33-8
   PubMedGoogle Scholar
• Sutton P, Doidge C, Pinczower G, et al. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol Med Microbiol 2007;50(2):213-19
   PubMedGoogle Scholar
• Stent A, Every AL, Ng GZ, et al. Helicobacter pylori thiolperoxidase as a protective antigen in single-and multi-component vaccines. Vaccine 2012;30(50):7214-20
   PubMedGoogle Scholar
• Every AL, Stent A, Moloney MB, et al. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011;29(7):1514-18
   PubMedGoogle Scholar
• Svennerholm AM, Lundgren A. Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol 2007;50(2):146-56
   PubMedGoogle Scholar
• Flach C-F, Svensson N, Blomquist M, et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 2011;29(6):1235-41
   PubMedGoogle Scholar
• Wang L, Liu X-F, Yun S, et al. Protection against Helicobacter pylori infection by a trivalent fusion vaccine based on a fragment of urease B-UreB414. J Microbiol 2010;48(2):223-8
   PubMedGoogle Scholar
• Kalbina I, Engstrand L, Andersson S, Strid Å. Expression of Helicobacter pylori TonB protein in transgenic Arabidopsis thaliana: toward production of vaccine antigens in plants. Helicobacter 2010;15(5):430-7
   PubMedGoogle Scholar
• Monteiro MA, Britton S, Applebee LA, Baqar S. Synthesis and immunogenicity of a Helicobacter pylori lipopolysaccharide-based conjugate. Vaccine 2011;29(17):3098-102
   PubMedGoogle Scholar
• Moss SF, Moise L, Lee DS, et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011;29(11):2085-91
   PubMed Web of Science ®Google Scholar
• Ihan A, Pinchuk IV, Beswick EJ. Inflammation, immunity, and vaccines for Helicobacter pylori infection. Helicobacter 2012;17(s1):16-21
   PubMedGoogle Scholar
• Iankov ID, Haralambieva IH, Galanis E. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 2011;29(8):1710-20
   PubMed Web of Science ®Google Scholar
• Bégué RE, Sadowska-Krowicka H. Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol 2010;60(2):142-6
   PubMedGoogle Scholar
• Qiu Y, Wang Y-C, Tao H-X, et al. Identification of B-cell epitopes in urease B subunit of Helicobacter pylori bound by neutralizing antibodies. Vaccine 2010;28(32):5220-7
   PubMed Web of Science ®Google Scholar
• Yang W-C, Chen L, Li H-B, et al. Identification of two novel immunodominant UreB CD4+ T cell epitopes in Helicobacter pylori infected subjects. Vaccine 2013;31(8):1204-9
   PubMedGoogle Scholar
• Li Y, Jiang Y, Xi Y, et al. Identification and characterization of H-2d restricted CD4+ T cell epitopes on Lpp20 of Helicobacter pylori. BMC immunol 2012;13(1):68
   PubMedGoogle Scholar